跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MCP-4
首页
药物
MCP-4
MCP-4
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
MCP-1 binding nucleic acids
US 8193159 B2
申请人: PURSCHKE WERNER
优先权: 2006
CN
US
7 件公开
Amino-terminally truncated MCP-2 as chemokine antagonists
US 6905676 B2
申请人: APPLIED RESEARCH SYSTEMS
优先权: 1997
US
4 件公开
Antibodies to MCP-4
US 7138498 B2
申请人: HUMAN GENOME SCIENCES INC
优先权: 2000
US
4 件公开
N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US 7629351 B2
申请人: BRISTOL MYERS SQUIBB CO
优先权: 2007
US
4 件公开
N-((IR,2S,5R)-5-(ISOPROPYL(METHYL)AMINO)-2-((S)-2-0XO-3-(6-TRIFLUOROMETHYL)QUINAZOLIN-4-YLAMINO)PYRROLIDIN-1-YL)CYCLOHEXYL)ACETAMIDE AND OTHER MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS.
US 7671062 B2
申请人: BRISTOL MYERS SQUIBB CO
优先权: 2006
CN
US
3 件公开
Population of multipotent cardiac precursor cells derived from human blastocysts derived stem cells
US 8802431 B2
申请人: SARTIPY PETER
优先权: 2007
EP
US
3 件公开
Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients
US 10765128 B2
申请人: KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY
优先权: 2015
CN
US
2 件公开
DAF-MCP CHIMERIC PROTEINS, PROCESS TO MANUFACTURE THE SAME AND USE OF THE CHIMERIC PROTEIN FOR TREATING PATHOLOGICAL CONDITIONS INVOLVING THE COMPLEMENT SYSTEM
EP 3956347 A4
申请人: NAT CENTRE FOR CELL SCIENCE
优先权: 2019
EP
US
2 件公开
BIOMARKER FOR PREDICTING SENSITIVITY OF RECTAL CANCER TO TREATMENT WITH AN0025 IN COMBINATION WITH RADIOTHERAPY/CHEMORADIOTHERAPY (RT/CRT)
WO 2024027599 A1
申请人: ADLAI NORTYE BIOPHARMA CO LTD
优先权: 2022
CN
WO
2 件公开
Therapeutics for chemokine mediated diseases
US 6706767 B2
申请人: CHEMOKINE THERAPEUTICS CORP
优先权: 2000
US
2 件公开
第 1 / 5 页
上一页
下一页
药物
反馈